Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Rhea-AI Summary

Dynavax Technologies (NASDAQ: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, after U.S. market close. The company will host a conference call and audio webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day.

Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18 and older, and CpG 1018 adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.

EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2025 financial results on Tuesday, May 6, 2025, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Tuesday, May 6, 2025, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B^® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018^® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visit www.dynavax.com.

For Investors/Media:

Paul Cox
pcox@dynavax.com
510-665-0499 

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2025-financial-results-and-host-conference-call-on-may-6-2025-302434859.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax (DVAX) release Q1 2025 earnings?

Dynavax will release Q1 2025 earnings on Tuesday, May 6, 2025, after U.S. financial markets close, followed by a conference call at 4:30 p.m. ET.

What are Dynavax's (DVAX) main commercial products in 2025?

Dynavax has two main commercial products: HEPLISAV-B vaccine for hepatitis B prevention and CpG 1018 adjuvant used in HEPLISAV-B and COVID-19 vaccines.

Where is HEPLISAV-B vaccine approved for use?

HEPLISAV-B is approved in the United States, European Union, and United Kingdom for preventing hepatitis B virus infection in adults 18 years and older.

How can investors access Dynavax's Q1 2025 earnings call?

Investors can access the earnings call through the live audio webcast on Dynavax's website under the 'Events & Presentations' page in the 'Investors' section.